Floatz Rating
B59/100
Confidence
Indicative
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
51High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07321015CT.gov A Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast Cance | — | Not Yet Recruiting | — | — | — |
NCT05928780CT.gov An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC in First-line Treatment (FUTURE-Trop2) | — | Unknown | — | — | — |
NCT05834582CT.gov Neoadjuvant Fluzoparib in Germline BRCA-mutated Three-negative Breast Cancer Breast Cancer | — | Unknown | — | — | — |
NCT05582499CT.gov Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy | — | Recruiting | — | — | — |
NCT03945604CT.gov A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC | — | Completed | — | — | — |
NCT03805399CT.gov FUSCC Refractory TNBC Umbrella (FUTURE) | — | Unknown | — | — | — |
NCT03075462CT.gov A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Triple-Negative Breast Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Fluzoparib (this asset) | Tianjin Medical University Cancer Institute and Hospital | P2 | B · 59 |
| Carboplatin | M.D. Anderson Cancer Center | P4 | BB |
| Capivasertib | AstraZeneca | P3 | BB |
| Cyclophosphamide | M.D. Anderson Cancer Center | P4 | BB |
| Veliparib | National Cancer Institute (NCI) | P3 | BB |
| Enzalutamide | Nuvation Bio Inc. | P2 | BB |
| Atezolizumab | European Institute of Oncology | P3 | BB |
| Famitinib | Fudan University | P3 | BB |
| Epirubicin | M.D. Anderson Cancer Center | P4 | BB |
+42 more in the Triple-Negative Breast Carcinoma cohort
Other indications for Fluzoparib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Primary Peritoneal Carcinoma | — | P3 | B · 62 |
| Malignant Pancreatic Neoplasm | — | P3 | B · 62 |
| Breast Carcinoma | — | P3 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Fluzoparib in Triple-Negative Breast Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/fluzoparib-triple-negative-breast-carcinoma-64435
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →